The University of Chicago Header Logo

Connection

Mark J. Ratain to Interleukin-2

This is a "connection" page, showing publications Mark J. Ratain has written about Interleukin-2.
Connection Strength

0.234
  1. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27.
    View in: PubMed
    Score: 0.053
  2. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol. 1998 Jul; 39(1):63-73.
    View in: PubMed
    Score: 0.039
  3. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998 Jan 15; 91(2):399-405.
    View in: PubMed
    Score: 0.038
  4. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer. 1997 Jan; 33 Suppl 1:S34-6.
    View in: PubMed
    Score: 0.035
  5. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Leuk Lymphoma. 1994 Jul; 14(3-4):257-62.
    View in: PubMed
    Score: 0.029
  6. A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a. Cancer. 1993 Apr 01; 71(7):2371-6.
    View in: PubMed
    Score: 0.027
  7. Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). Invest New Drugs. 2004 Jan; 22(1):83-9.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.